BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28498503)

  • 1. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway.
    Lu H; Liu Y; Wang D; Wang L; Zhou H; Xu G; Xie L; Wu M; Lin Z; Yu Y; Li G
    Tumour Biol; 2016 Aug; 37(8):11469-77. PubMed ID: 27012551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
    Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
    Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
    Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
    Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.
    Zhang L; Blackwell K; Workman LM; Chen S; Pope MR; Janz S; Habelhah H
    Mol Cell Biol; 2015 Oct; 35(19):3324-38. PubMed ID: 26195820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
    Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
    Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
    Liu YK; Jia YJ; Liu SH; Ma J
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
    Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
    Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
    Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D
    Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.
    Yu H; Su J; Xu Y; Kang J; Li H; Zhang L; Yi H; Xiang X; Liu F; Sun L
    Eur J Cancer; 2011 Jul; 47(10):1585-94. PubMed ID: 21371883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of microRNA-100 and its correlation with drug resistance in human ovarian cancer SKOV3/DDP cells].
    Guo P; Peng D; Xiong X; Zhang S
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1624-7. PubMed ID: 26607088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
    Yu JL; Gao X
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
    Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
    Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
    Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
    Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.